Amprion Secures $15 Million in Series B Funding to Advance Precision Medicine for Neurodegenerative Disorders

Amprion, a trailblazer in precision medicine for neurodegenerative disorders, has successfully raised $15 million in a recent funding round to further its mission of transforming the diagnosis and management of conditions like Parkinson's disease (PD), Lewy body dementia (LBD/DLB), and Alzheimer’s disease (AD) with Lewy body variant. The funding will be specifically directed towards enhancing the development and commercialization of its innovative SAAmplify™-ɑSYN biomarker test, a first-in-class qualitative Laboratory Developed Test (LDT). As the only seed amplification assay currently available for aiding the diagnosis of synucleinopathies, Amprion’s groundbreaking technology presents a significant advancement in identifying these challenging-to-diagnose conditions early on, thereby opening new avenues for targeted treatment strategies. With this capital infusion, the company plans to bolster its research initiatives, expand clinical partnerships, and streamline regulatory processes to bring this life-changing diagnostic tool to patients and healthcare providers more swiftly. Amprion’s commitment to addressing the increasing global burden of neurodegenerative disorders is clear, and with the support of this funding, the company is poised to enhance patient outcomes by providing a more accurate and reliable method of diagnosis. As Amprion continues to spearhead innovation in the field of precision medicine, healthcare professionals and patients alike can look forward to the transformative impact of its advanced diagnostic solutions on the landscape of neurodegenerative disease management.